Alan D. Betensley, MD, is a board-certified pulmonologist and associate professor at the Feinberg School of Medicine in Northwestern Medicine.

Maintenance ECP Linked to Survival Benefit in BOS After Lung Transplant, With Alan Betensley, MD

Maintenance extracorporeal photopheresis (ECP) following an initial treatment phase was independently associated with enhanced survival among lung transplant recipients with 

), according to a late-breaking poster at the 

American Thoracic Society (ATS) International Conference 2026

Bronchiolitis obliterans syndrome remains the most common phenotype of chronic lung allograft dysfunction and a leading cause of long-term morbidity and mortality after lung transplantation.

 Extracorporeal photopheresis has previously been associated with stabilization of lung function in observational studies of BOS, although randomized controlled trial data remain limited.

“We really don't have a lot of treatments with proven survival benefit for recipients who develop chronic lung allograft dysfunction and, in this case, bronchiolitis obliterans syndrome,” investigator Alan Betensley, MD, from Northwestern University, told 

. “Anything that could improve long-term survival would really be a benefit to lung transplant patients.”

The analysis, led by George Despotis, MD, from the Washington University School of Medicine, evaluated data from a prospective Medicare-approved clinical trial registry involving patients with chronic lung allograft dysfunction refractory to standard immunosuppressive therapies. Investigators observed that recipients who continued maintenance ECP after the initial 6-month treatment phase demonstrated improved long-term survival compared with those who discontinued therapy.

The registry enrolled 258 lung transplant recipients across 20 US transplant centers. Participants received 24 ECP procedures during a 6-month induction period, with continuation into maintenance therapy left to the discretion of treating clinicians. Investigators assessed changes in forced expiratory volume in 1 second (FEV

) decline and evaluated survival outcomes using Cox proportional hazards regression models adjusted for demographic, operative, and clinical covariates.

Among 191 participants assigned to ECP treatment, investigators observed an 89% reduction in FEV

decline 12 months after ECP initiation. However, Betensley cautioned against overinterpreting physiologic improvement in the absence of matched controls.

“In this population of patients with bronchiolitis obliterans syndrome, even without any treatment, we typically do see that the rate of reduction in FEV

does decrease over time,” Betensley said. “We're going to know a little bit more if we have some good, matched control patients to compare to.”

The survival analysis focused on 159 participants who survived at least 6 months after ECP initiation. Investigators found patients who did not receive maintenance ECP had significantly worse survival outcomes compared with those who continued maintenance therapy. The association persisted after multivariate adjustment, with maintenance ECP independently associated with improved survival.

Still, Betensley noted the observational nature of the analysis limits conclusions regarding causality. Because ECP is burdensome, involving repeated procedures over months, clinicians may have selectively continued maintenance therapy in patients who were less clinically fragile.

“The patients who ended up continuing with maintenance therapy may have been less sick or more robust than the patients who didn't receive maintenance treatment,” Betensley said. “Without having any type of control, we can't be certain that it's a survival benefit because it may be that the patients who were sicker were selected not to continue with the maintenance ECP.”

The findings may help inform individualized discussions regarding continuation of maintenance therapy after the induction phase, particularly among patients tolerating treatment without substantial adverse effects.

“If a patient is tolerating it without adverse side effects… it probably makes sense to continue with the maintenance ECP,” Betensley said. “Ultimately, these have to be individualized decisions on a patient-by-patient basis.”

Investigators indicated a risk-adjusted control cohort is being pursued to support a future petition to the Centers for Medicare & Medicaid Services to expand national coverage for ECP in BOS under updated CMS scientific guidelines.

Editor’s note: Disclosures for Betensley include Melinta Therapeutics, Merck Sharp & Dohme, Regeneron Healthcare Solutions, and ABBVIE.

) Analysis of Data From a Prospective Medicare Approved Clinical Trial Registry Indicates That Use of Maintenance Extracorporeal Photopheresis Is Independently Associated With Enhanced Survival of Lung Allograft Recipients Who Have Developed Life-Threatening Chronic Lung Allograft Rejection (Bronchiolitis Obliterans Phenotype) Refractory to Standard of Care Immunosuppressive Therapy. Poster presented at ATS 2026 on May 17 in Orlando, Florida.

Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. 

Pilewski J. Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome. UpToDate. Published April 2026. Accessed May 17, 2026. 

https://www.uptodate.com/contents/chronic-lung-allograft-dysfunction-bronchiolitis-obliterans-syndrome/print

Videos

Maintenance extracorporeal photopheresis was associated with improved survival in lung transplant recipients with bronchiolitis obliterans syndrome, according to Alan Betensley, MD.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Pediatric pulmonary rehabilitation was associated with significant improvements in exercise tolerance, strength, and quality of life (QoL) among children with 

, according to new findings presented at the 

American Thoracic Society (ATS) 2026 International Conference

 in Orlando, Florida. The study found that children in the program experienced meaningful functional gains despite no significant changes in pulmonary function testing (PFT).

“This highlights that meaningful clinical improvement extends beyond spirometry and supports PR as an important component of care for children with chronic respiratory disease,” lead author Tauras Vucianis, a third-year medical student at University of Cincinnati College of Medicine, said in a statement.

Pulmonary rehabilitation is well established in adults, with ATS guidelines strongly recommending it for stable COPD in 2023 based on moderate-quality evidence.

 However, pediatric programs remain uncommon because of limited data, lack of standardized protocols, and the need for age- and function-specific exercise approaches.

To evaluate the feasibility and outcomes of pediatric pulmonary rehabilitation, Vucianis and colleagues retrospectively examined children who completed a pulmonary rehabilitation program between March 2017 and August 2025 at Cincinnati Children’s Hospital Medical Center. Eligibility criteria required completion of a baseline evaluation and participation in ≥ 5 rehabilitation sessions.

The study included 51 unique patients, with a mean age of 14.4 years; 55% were male. Underlying lung disease patterns were classified as obstructive in 45%, restrictive in 39%, and mixed in 6% of participants. Program duration averaged 18.8 sessions, with approximately 9 days between sessions.

Although spirometric measures remained stable after rehabilitation, investigators observed statistically significant improvements across multiple exercise and functional performance measures. The 6-minute walk test distance increased from 1234.5 feet at baseline to 1464.6 feet following pulmonary rehabilitation (

 =.0001). Functional strength measures also improved substantially, including 30-second sit-to-stand repetitions, which increased from 13.7 to 17.9 repetitions (

 =.0002), and modified push-ups, which increased from 15.4 to 27.6 repetitions (

 =.0022). Performance on the 8-foot-up-and-go test improved as well, with times decreasing from 4.48 seconds to 3.88 seconds (

Patient-reported quality of life outcomes similarly improved after rehabilitation. Pediatric Quality of Life Inventory (PedsQL) scores increased from 64.95 to 70.74 among patients (

 =.027), while parent-reported scores improved from 60.67 to 68.40 (

Patients and caregivers favorably viewed the rehabilitation program, supporting the feasibility and acceptability of pediatric pulmonary rehabilitation implementation in clinical practice.

“One of the main goals of our program is to increase patients’ confidence in the self-management of their disease and to promote physical activity outside of the medical facility,” Vucianis said. “We are always thrilled to hear when our former participants are continuing to implement their own exercise programs long after their [pulmonary rehabilitation] sessions have ended.”

Investigators said future research will evaluate the durability of rehabilitation benefits, optimal timing of intervention, and the impact of pediatric [pulmonary rehabilitation] on additional clinical outcomes among children with chronic respiratory diseases.

Another Program-Focused Study Presented at ATS 2026

A study found the NYC Public Housing Mold Program, known as NYCHA’s Mold Busters initiative, was associated with a significant reduction in asthma-related emergency department (ED) visits. Investigators reported an average decrease of 9 asthma ED visits per 1000 residents annually.

Across NYCHA public housing developments, this translated to an estimated 2798 fewer asthma-related ED visits per year from 2021 to 2023. Investigators linked the Mold Busters program, focused on mold remediation, ventilation improvements, and faster complaint response times, to reduced asthma burden in low-income, high-risk communities.

Analysis using differences-in-differences methods suggested asthma ED visits would have been about 25% greater without the intervention. Buildings with the steepest declines in mold complaints also saw the largest reductions in asthma ED visits, reinforcing the impact of large-scale housing-based environmental health interventions.

Vucianis T, Foster K, Nakamura A, et al. Benefits of Pulmonary Rehabilitation for Pediatric Chronic Respiratory Disease. Poster presented at ATS 2026 in Orlando, Florida, on May 17, 2026. 

https://ats2026.d365.events/education/abstracts/abstracts/1395cb7b-e3a2-4a0d-a091-447fc457daaf

Pediatric pulmonary rehab improves exercise ability, quality of life. EurekAlert! Published on May 17, 2026. Accessed May 16, 2026. 

https://www.eurekalert.org/news-releases/1127720

Rochester CL, Alison JA, Carlin B, et al. Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. 

Flores N, Casey J, Lovinsky-Desir S, et al. Large-Scale Mold Intervention Reduced Asthma Emergency Department Visits in New York City Public Housing Differentially Across Building and Neighborhood Characteristics. Poster presented at ATS 2026 in Orlando, Florida, on May 17, 2026.

Articles

Retrospective evaluation of a pediatric pulmonary rehabilitation program at Cincinnati Children’s (2017–2025) included 51 adolescents with obstructive, restrictive, or mixed chronic lung disease completing a mean 18.8 sessions. Spirometry remained unchanged, yet functional capacity improved: 6-minute walk distance, sit-to-stand, push-ups, and 8-foot-up-and-go all showed significant gains. Patient- and parent-reported PedsQL scores increased, and participants endorsed feasibility, acceptability, and sustained self-management behaviors in routine practice. Separately, NYCHA’s Mold Busters remediation program across NYC public housing correlated with ~25% fewer asthma ED visits and ~2798 avoided visits annually.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonary Rehabilitation Boosts QoL in Pediatric Chronic Respiratory Disease

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Concomitant use of ixekizumab and tirzepatide significantly improves rates of complete skin clearance in addition to meaningful weight loss in adults with 

 and overweight or obesity, new data suggest, compared with ixekizumab alone.

 and resulting from a phase 3b clinical trial conducted across 72 US sites, were authored by investigators such as Mark Lebwohl, MD, from the Icahn School of Medicine at Mount Sinai. The randomized, multicenter, open-label study included blinded assessors for psoriasis-specific evaluations.

Previous clinical trial data on patients with psoriatic arthritis (PsA) and overweight or obesity suggested  concomitant ixekizumab and tirzepatide led to joint disease and quality of life improvements along with weight reductions.

“In this article, we describe the TOGETHER-PsO trial, which evaluated the efficacy and safety of [ixekizumab] as concomitantly administered with [tirzepatide] compared with [ixekizumab] alone in participants with moderate to severe psoriasis and overweight or obesity,” Lebwohl and colleagues wrote.

Trial Design and Findings on Ixekizumab + Tirzepatide

Investigators initiated the trial in September 2024, with the primary endpoint assessed at the 36-week mark on January 8, 2026. The team’s full 52-week analysis is slated to end in May 2026. Lebwohl et al set out to assess the combination regimen’s efficacy and safety in adult patients living with longstanding moderate-to-severe plaque psoriasis.

In order to qualify, those included were required to have had psoriasis for at least 6 months, showing a Static Physician Global Assessment (sPGA) score of at least 3. Additionally, they would be required to have a Psoriasis Area and Severity Index (PASI) score of 12 or more and involvement of1 0% body surface area (BSA) at minimum. They also had to meet criteria for either overweight or obesity, including those with body mass index (BMI) values between 27 - 30 accompanied by at least 1 weight-related comorbidity, or a BMI of 30 or greater.

Lebwohl and coauthors randomly assigned approved participants in a 1:1 ratio to be treated either with a subcutaneous ixekizumab injection plus tirzepatide or ixekizumab as a monotherapy. Their randomization of these individuals was stratified according to sex, previous exposure to advanced psoriasis medications, and BMI category.

Ixekizumab dosing consisted of 160 mg at baseline followed by 80 mg on an every-2-week basis through Week 12 and every 4 weeks thereafter. Tirzepatide use began at 2.5 mg weekly for the first month, with dose escalation taking place every 4 weeks in 2.5-mg increments until those evaluated saw a tolerated maintenance dose of 5 mg, 10 mg, or 15 mg by the 32-week mark.

In total, the investigative team randomized 274 participants. The cohort had a mean age of 45.6 years, and nearly 45% were women. Participants had a mean BMI of 39.2 and an average psoriasis disease duration of approximately 15 years. Mean baseline PASI score was 19.7. By week 36, 84.3% of enrolled participants had completed treatment.

In Lebwohl and coauthors’ primary endpoint analysis, they found 27.1% of subjects on the ixekizumab-tirzepatide combination treatment simultaneously saw complete skin clearance (PASI 100) and at least 10% dip in body weight. In contrast, only 5.8% of subjects treated with only ixekizumab met the same combined endpoint, representing a statistically significant difference.

Higher rates of PASI 100 attainment were seen in the combination arm overall, with the investigators noting 40.6% achieved complete clearance compared and 29.0% in the monotherapy arm. Additionally, Lebwohl et al found nearly 80% of patients on combination therapy saw PASI 75 scores alongside at least 5% reductions in weight. This was compared with fewer than 20% in the ixekizumab-only cohort. Rates of at least 10% weight loss were also shown to be significantly higher with the addition of tirzepatide.

The study’s safety results aligned with the established profiles of both medications, with gastrointestinal adverse events (AEs) and injection-site reactions found to be the most commonly reported treatment-emergent AEs. Lebwohl and colleagues noted gastrointestinal effects appeared more frequently in those treated with the combination regimen.

“Combined, the findings from this trial support the multifaceted health benefits of concomitant therapy with IXE and TZP for treating psoriasis and management of comorbidities and may help to inform future clinical practice and guideline recommendations for these patients,” they wrote.

Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. Published online May 15, 2026. 

Garvey WT, Frias JP, Zhang XM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.

Concomitant ixekizumab plus tirzepatide improved combined dermatologic and metabolic outcomes in adults with longstanding moderate-to-severe plaque psoriasis and overweight/obesity. In TOGETHER-PsO, 274 participants were randomized 1:1 across 72 US sites with blinded psoriasis assessments. By week 36, the combination significantly increased simultaneous PASI 100 and ≥10% weight loss versus ixekizumab alone, and also improved PASI 100 and PASI 75 with meaningful weight reduction. Adverse events were consistent with known safety profiles, with more gastrointestinal events on combination therapy.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ixekizumab + Tirzepatide Improves Psoriasis, Reduces Weight in Those with Obesity

Nina Flores, PhD I Image Credit: The University of Texas at Austin School of Social Work

A large-scale mold remediation initiative implemented across New York City public housing developments was associated with substantial reductions in asthma-related emergency department (ED) visits, according to findings presented at the 

Investigators reported that the New York City Housing Authority’s (NYCHA) Mold Busters program was associated with an average annual reduction of 9 asthma-related ED visits per 1000 residents (95% confidence interval [CI], -11.2 to -6.6), translating to an estimated 2798 fewer ED visits annually from 2021 to 2023.

“These results suggest that housing interventions on asthma triggers could play a critical role in reducing long-standing asthma disparities,” lead author Nina Flores, PhD, said in a statement.

Flores conducted the work as a doctoral student at Columbia University and is now a postdoctoral fellow at The University of Texas at Austin School of Social Work and Dell Medical School.

Asthma burden remains disproportionately high among residents of public housing, particularly in low-income Black and Hispanic communities.

 NYCHA houses more than 400,000 residents, and mold complaints have been a longstanding concern. The Mold Busters program was launched in 2019 following a 2013 class-action lawsuit filed by residents who alleged mold exposure contributed to asthma morbidity.

The intervention included evidence-based mold remediation practices, improved response timelines for mold complaints, staff training, and ventilation improvements throughout NYCHA buildings.

 Prior randomized studies involving fewer than 100 participants suggested mold remediation could improve asthma symptoms, but evidence evaluating citywide implementation has been limited.

To assess the impact of the program, investigators analyzed building-level asthma ED visit data from 2016 through 2023 among NYCHA residents and compared outcomes with residents living in nearby lower-income, non-NYCHA census tracts.

 Using doubly robust differences-in-differences analyses, investigators compared pre-intervention outcomes from 2016 to 2018 with post-intervention outcomes from 2021 to 2023.

The findings suggested that, without the Mold Busters intervention, NYCHA residents would have experienced approximately 25% more asthma-related ED visits during the post-intervention period.

The team also evaluated resident-reported mold work orders across buildings using latent class growth analysis to identify trends in mold complaint trajectories after the intervention.

 Five trajectory groups emerged, with all groups experiencing declines in mold reporting rates after program implementation. However, the magnitude of improvement varied considerably across buildings.

Buildings with slower declines in mold complaints were generally older, larger, less likely to have mechanical ventilation, and more frequently located in flood zones and neighborhoods with greater poverty. In contrast, buildings with steeper reductions in mold complaints also experienced the greatest decreases in asthma-related ED visits.

According to Flores, the relationship between declining mold complaints and reduced ED utilization further supports the effectiveness of the intervention.

Investigators noted the study likely underestimates the broader health benefits of mold remediation because analyses focused specifically on ED visits rather than milder asthma exacerbations, missed school or workdays, or other respiratory and allergic conditions linked to mold exposure.

“The health benefits reported here likely underestimate the full scope of health-related benefits from the intervention,” Flores said.

The research team plans to continue evaluating outcomes as additional data become available to determine whether benefits persist or increase over time. Ongoing work is also examining fungal exposure, allergic sensitization, and asthma-related illnesses among children living in NYCHA housing before and after mold remediation efforts.

Flores N, Casey J, Lovinsky-Desir S, et al. Large-Scale Mold Intervention Reduced Asthma Emergency Department Visits in New York City Public Housing Differentially Across Building and Neighborhood Characteristics. Poster presented at ATS 2026 in Orlando, Florida on May 17, 2026.

Public housing mold intervention program reduces asthma-related ED visits. EurekAlert! Published on May 17, 2026. Accessed May 16, 2026. 

https://www.eurekalert.org/news-releases/1127655

A citywide mold remediation and ventilation initiative in New York City public housing correlated with meaningful declines in asthma morbidity as measured by emergency department utilization. Across 2021–2023, the program was associated with an average annual reduction of 9 asthma-related ED visits per 1,000 residents, equating to roughly 2,798 fewer visits per year, and an estimated 25% higher visit burden absent the intervention. Benefits were heterogeneous across buildings, aligning with differential improvements in resident-reported mold complaints and structural/environmental risk factors.

A study presented at the ATS 2026 found the New York City Housing Authority’s Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

NYC Public Housing Mold Program Linked to Fewer Asthma ED Visits

Patricia Fechner, MD, is the attending physician at Seattle Children’s Hospital and a professor of pediatrics at the University of Washington School of Medicine.

Crinecerfont Maintains Improvements in Pediatric CAH at 2 Years, With Patricia Fechner, MD

 treated with crinecerfont have shown lower glucocorticoid doses and reduced symptoms, according to 2-year data from the CAHtalyst Pediatric study.

“I think we are approaching a true tradeoff now,” Patricia Fechner, MD, attending physician at Seattle Children’s Hospital and a professor of pediatrics at the University of Washington School of Medicine, told 

 in an exclusive interview. “We no longer need to dose our glucocorticoids for treatment of CAH to suppress the adrenal androgens and to replace the adrenal insufficiency – we can separate those 2 mechanisms and just give the glucocorticoid dosing for adrenal insufficiency and then give the crinecerfont to maintain lower doses of adrenal androgens.”

The CAHtalyst Pediatric study is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of crinecerfont in children. It was conducted across 46 locations worldwide and included patients with a medically confirmed diagnosis of classic CAH due to 21-hydroxylase deficiency who were on a stable steroid regimen and had elevated androgen levels. Patients with any other forms of classic CAH, a history of bilateral adrenalectomy, hypopituitarism, or other conditions needed chronic glucocorticoid therapy, or a history of cancer, among other criteria, were excluded.

Patients were randomly assigned in a 2:1 ratio to receive either crinecerfont as a solution or capsule, administered orally twice daily for 28 weeks or matching placebo. A stable glucocorticoid dose was maintained for 4 weeks, followed by an adjustment to 8 to 10 mg per square meter of body surface area per day, so long as androstenedione levels were controlled. Following the initial 28-week period, the placebo patients crossed over to crinecerfont for ≥24 weeks.

The primary outcome was change from baseline in serum androstenedione at week 4, measured via blood serum samples. Secondary outcomes included change in serum 17-hydroxyprogesterone at week 4, percent change in glucocorticoid daily dose at week 28, and change from baseline in the ratio of bone age to chronological age at week 28.

A total of 103 patients were randomized – 69 were assigned to crinecerfont and 34 to placebo. Of these, 100 (97%) remained in the trial at 28 weeks. The mean glucocorticoid dose at baseline was 16.4 mg per square meter per day, and the mean androstenedione level was 15 nmol/L. By week 4, investigators noted substantially reduced androstenedione in the crinecerfont group (-6.9 nmol/L) and a concurrent increase in the placebo group (2.5 nmol/L). By week 28, mean glucocorticoid had decreased by 18% with crinecerfont but increased by 5.6% in the placebo arm.

The present 2-year data follow these trends, with patients continuing to experience significant reductions in adrenocorticotropic hormone and 17-hydroxyprogesterone while achieving lower glucocorticoid doses. The analysis included 86 patients who had completed 2 years of treatment in the open-label extension period. Meaningful reductions were observed across hormone control, excess androgens, and long-term supraphysiologic glucocorticoid exposure – in addition, treatment was well-tolerated, with >80% study retention by 2 years and no new safety signals.

“This is the first new medication in over 70 years,” Fechner said. “It has changed how we treat CAH, and I think families wanted to be in the study. It was well tolerated, and patients’ parents were able to see the results of improvement in growth, their management of CAH, and the decrease in hydrocortisone dosing that their children needed.”

Editors’ Note: Fechner reports disclosures with Neurocrine Biosciences, Spruce Biosciences, and Neurocrine Ltd.

Neurocrine Biosciences. Neurocrine Biosciences Presents New Two-Year CRENISSITY (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia. 

https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-durable-hormone-control-reduced-glucocorticoid-exposure-and-meaningful-clinical-improvements-in-pediatric-patients-with-classic-congenital-302759774.html

Neurocrine Biosciences. Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study). ClinicalTrials.gov Identifier: NCT04806451. Updated February 5, 2025. Accessed May 15, 2026. 

https://clinicaltrials.gov/study/NCT04806451

Sarafoglou K, Kim MS, Lodish M, et al. Phase 3 trial of Crinecerfont in pediatric congenital adrenal hyperplasia. New England Journal of Medicine. 2024;391(6):493-503. 

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hormonal Disorders

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Hematology

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 05/10

Barry A. Borlaug, MD is a cardiologist in Rochester, Minnesota, affiliated with the Mayo Clinic.

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Updated HFmrEF Guidelines From HFSA Support Standard HFrEF Treatment

Patients with atopic dermatitis and prurigo nodules (AD-PN) saw notable itch reduction in 12 weeks after initiating upadacitinib.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

ADMIRE: Upadacitinib Efficacious in Atopic Dermatitis with Prurigo Nodules

Marc Ruel, MD, MPH, is a professor and the endowed chair and director of minimally invasive cardiac research in the division of cardiac surgery at the University of Ottawa Heart Institute.

Marc Ruel, MD, MPH, discusses the progress made since in the 11 years since the last guidelines, both in treatment and therapy.

Arrhythmia

Dyslipidemia

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

AHA Releases Updated Guidelines for Secondary Prevention Post-CABG

Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

TMS for MDD Reimagined: Faster, Fewer Visits, and Now at Home

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Strategic Alliance Partnership

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

Podcasts

In this May episode of The Medical Sisterhood podcast, the show features guest Lisa Swanson, MD, discussing the emotional realities of pediatric dermatology.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: The Hidden Cost of Being the Compassionate Doctor, With Lisa Swanson MD

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

Bruce Strober, MD, PhD, introduces a practical framework for determining when differences in efficacy between psoriasis treatments are clinically meaningful.

Risankizumab vs Icotrokinra for Psoriasis 

Bruce Strober, MD, PhD, compares agents within the IL-23 inhibitor class on dosing schedule and joint outcome data, and explains why long-term drug survival has become a central consideration in biologic selection for psoriasis.

Latest News

Maintenance ECP Linked to Survival Benefit in BOS After Lung Transplant, With Alan Betensley, MD

Pulmonary Rehabilitation Boosts QoL in Pediatric Chronic Respiratory Disease

Ixekizumab + Tirzepatide Improves Psoriasis, Reduces Weight in Those with Obesity

NYC Public Housing Mold Program Linked to Fewer Asthma ED Visits

Crinecerfont Maintains Improvements in Pediatric CAH at 2 Years, With Patricia Fechner, MD